Cases of MTC in sufferers handled with liraglutide, A further GLP-1 receptor agonist, have already been reported while in the postmarketing interval; the info in these stories are inadequate to determine or exclude a causal partnership among MTC and GLP-one receptor agonist use in humans. to reduce the potential risk of kidney disorder worsening